Radiolabeled Monoclonal Antibody in Treating Patients With Progressive Metastatic Androgen-Independent Adenocarcinoma (Cancer) of the Prostate

Completed · Phase 2

Conditions studied: Prostate Cancer

In brief

RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver radioactive tumor-killing substances to them without harming normal cells. PURPOSE: This phase II trial is studying how well radiolabeled monoclonal antibody works in treating patients with progressive metastatic androgen-independent adenocarcinoma (cancer) of the prostate.

Key facts

Study ID

NCT00081172

Run by

Memorial Sloan Kettering Cancer Center

Starts

2004-01-01

Expected to finish

2006-05-01

Last updated by the study team

2013-07-10

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• Memorial Sloan-Kettering Cancer Center — New York, New York, United States
• New York Weill Cornell Cancer Center at Cornell University — New York, New York, United States
• Herbert Irving Comprehensive Cancer Center at Columbia University — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.